Replies to post #145918 on Biotech Values

[jq1234]

Yes, I was really surprised to see the PR today. I assume it has a lot to do with this:

the Janssen AI and Pfizer Joint Steering Committee for the AIP has decided that participants from this study who enrolled in a follow-on extension study will no longer receive doses of bapineuzumab.

I think PFE most likely felt they had obligation to release the result now, NOT until Sept.

[masterlongevity]

i agree. this is indeed very interesting. They clearly stated they would not release until both trial results were in, if negative or positive. Even the quotes about the data are from Pfe, yet pfizer had nothing to do with the conduct of the trial

[iandy]

Give PFE credit for not being a party to a cover-up. I’ll bet JNJ’s lawyers threatened PFE with breach of contract for speaking out of turn, and PFE told them to go fly a kite.

The fact JNJ had said no information would be released on either of the two trials until the full datasets from both trials were presented at a medical conference might be why PFE was the one to make the announcement. JNJ was spared having to explain why they were disclosing the results from one of the trials now.

It's also possible neither of them wanted to do it and PFE lost the coin toss.

There are other possible explanations.
Granted JNJ has not been very forthcoming lately,
I think we sometimes jump to conclusions based on bias.